Fennec Pharmaceuticals Inc.
06/10/2026 | Press release | Distributed by Public on 06/10/2026 15:19
Proxy Results (Form 8-K)
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 10, 2026, Fennec Pharmaceuticals Inc. (the "Company") held an annual meeting of shareholders (the "Meeting"). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:
1. The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:
| Name of Nominee | Votes For | Votes Withheld | Broker Non-Votes |
| Dr. Khalid Islam | 20,246,596 | 126,891 | 5,881,885 |
| Chris A. Rallis | 20,126,058 | 247,429 | 5,881,885 |
| Marco Brughera | 20,237,230 | 136,257 | 5,881,885 |
| Jodi Cook | 20,191,538 | 181,949 | 5,881,885 |
| Jeffrey Hackman | 20,282,707 | 90,780 | 5,881,885 |
2. The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:
| Votes For | 26,091,716 |
| Votes Withheld | 134,491 |
| Votes Against | 29,165 |
| Broker Non-Votes | 0 |
3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:
| Votes For | 19,326,750 |
| Votes Against | 336,060 |
| Abstentions | 710,677 |
| Broker Non-Votes | 5,881,885 |
4. The resolution to vote on the advisory vote on the frequency of advisory votes on compensation of Corporations named executive officers was approved based on the following vote:
| Votes For Evey One Year | 18,235,648 |
| Votes For Evey Two Years | 2,326 |
| Votes For Evey Three Years | 2,086219 |
| Abstentions | 49,294 |
5. The resolution to approve certain amendments to Corporation's 2020 Equity Incentive Plan was approved based on the following vote:
| Votes For(1) | 17,425,439 |
| Votes Against | 1,429,951 |
| Abstentions | 751,944 |
| Broker Non-Votes | 5,881,885 |
(1) An aggregate of 766,153 common shares, representing the aggregate number of shares held by officers and directors of the Corporation, has been deducted from the FOR vote in respect of this resolution.
6. The resolution to ratify and approve the adoption of Fennec's 2026 Equity Inducement Plan was approved based on the following vote:.
| Votes For | 18,626,207 |
| Votes Against | 1,033,779 |
| Abstentions | 713,501 |
| Broker Non-Votes | 5,881,885 |
Fennec Pharmaceuticals Inc. published this content on June 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 10, 2026 at 21:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]